JPWO2021078889A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021078889A5 JPWO2021078889A5 JP2022523485A JP2022523485A JPWO2021078889A5 JP WO2021078889 A5 JPWO2021078889 A5 JP WO2021078889A5 JP 2022523485 A JP2022523485 A JP 2022523485A JP 2022523485 A JP2022523485 A JP 2022523485A JP WO2021078889 A5 JPWO2021078889 A5 JP WO2021078889A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- compound
- treatment
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 3
- 208000007056 sickle cell anemia Diseases 0.000 claims 3
- 208000002903 Thalassemia Diseases 0.000 claims 2
- 208000035868 Vascular inflammations Diseases 0.000 claims 2
- 206010053648 Vascular occlusion Diseases 0.000 claims 2
- 238000002648 combination therapy Methods 0.000 claims 2
- 150000003840 hydrochlorides Chemical class 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- 208000021331 vascular occlusion disease Diseases 0.000 claims 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 229960001330 hydroxycarbamide Drugs 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000018191 liver inflammation Diseases 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 229940124641 pain reliever Drugs 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 150000003892 tartrate salts Chemical class 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962924556P | 2019-10-22 | 2019-10-22 | |
| EP19000483 | 2019-10-22 | ||
| EP19000483.8 | 2019-10-22 | ||
| US62/924,556 | 2019-10-22 | ||
| EP20163777 | 2020-03-17 | ||
| EP20163777.4 | 2020-03-17 | ||
| EP20176336.4 | 2020-05-25 | ||
| EP20176336 | 2020-05-25 | ||
| PCT/EP2020/079802 WO2021078889A1 (en) | 2019-10-22 | 2020-10-22 | Methods and compositions for treating sickle cell disease with a ferroportin inhibitor (vit-2763) |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023500060A JP2023500060A (ja) | 2023-01-04 |
| JP2023500060A5 JP2023500060A5 (https=) | 2023-06-06 |
| JPWO2021078889A5 true JPWO2021078889A5 (https=) | 2023-06-06 |
| JP7594004B2 JP7594004B2 (ja) | 2024-12-03 |
Family
ID=73005635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022523485A Active JP7594004B2 (ja) | 2019-10-22 | 2020-10-22 | フェロポーチン阻害剤（ｖｉｔ－２７６３）を用いる鎌状赤血球症を治療するための方法及び組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220274973A1 (https=) |
| EP (1) | EP4048262A1 (https=) |
| JP (1) | JP7594004B2 (https=) |
| KR (1) | KR20220086563A (https=) |
| CN (1) | CN114765955B (https=) |
| AU (1) | AU2020369137A1 (https=) |
| BR (1) | BR112022007616A2 (https=) |
| CA (1) | CA3154524A1 (https=) |
| IL (1) | IL291137A (https=) |
| MX (1) | MX2022004806A (https=) |
| WO (1) | WO2021078889A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025535398A (ja) | 2022-10-21 | 2025-10-24 | ビフォー （インターナショナル） エージー | 二環式フェロポーチン阻害剤 |
| EP4731218A1 (en) | 2023-06-26 | 2026-04-29 | Vifor (International) AG | Ferroportin-inhibitors for the use in the treatment of hereditary haemochromatosis (hh) |
| WO2026041650A1 (en) | 2024-08-20 | 2026-02-26 | Vifor (International) Ag | Ferroportin-inhibitors for the use in the treatment of lupus nephritis |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3002416C (en) | 2015-10-23 | 2023-10-24 | Vifor (International) Ag | Benzimidazolyl derivatives for use as ferroportin inhibitors |
| US11191818B2 (en) * | 2016-08-04 | 2021-12-07 | Takeda Pharmaceutical Company Limited | Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome |
| JOP20180036A1 (ar) * | 2017-04-18 | 2019-01-30 | Vifor Int Ag | أملاح لمثبطات فروبورتين جديدة |
| ES2934492T3 (es) | 2018-12-13 | 2023-02-22 | Global Blood Therapeutics Inc | Inhibidores de ferroportina y métodos de uso |
-
2020
- 2020-10-22 AU AU2020369137A patent/AU2020369137A1/en active Pending
- 2020-10-22 JP JP2022523485A patent/JP7594004B2/ja active Active
- 2020-10-22 EP EP20796575.7A patent/EP4048262A1/en active Pending
- 2020-10-22 MX MX2022004806A patent/MX2022004806A/es unknown
- 2020-10-22 BR BR112022007616A patent/BR112022007616A2/pt unknown
- 2020-10-22 US US17/636,575 patent/US20220274973A1/en not_active Abandoned
- 2020-10-22 CA CA3154524A patent/CA3154524A1/en active Pending
- 2020-10-22 CN CN202080074094.0A patent/CN114765955B/zh active Active
- 2020-10-22 WO PCT/EP2020/079802 patent/WO2021078889A1/en not_active Ceased
- 2020-10-22 KR KR1020227012237A patent/KR20220086563A/ko active Pending
-
2022
- 2022-03-06 IL IL291137A patent/IL291137A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6353577B2 (ja) | 組み合わせ組成物 | |
| US20070275933A1 (en) | Method for the treatment of acne | |
| EP2222314A1 (en) | Method and means for obtaining bronchorelaxation | |
| JPS59193821A (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| US20250302871A1 (en) | Colonic purgative composition | |
| EP4520394A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| US20170319519A1 (en) | Combination for the treatment of conditions involving muscular pain | |
| JPWO2021078889A5 (https=) | ||
| FI4199922T3 (fi) | (1r,3s)-3-((5-syano-4-fenyylitiatsol-2-yyli)karbamoyyli)syklopentaani-1-karboksyylihappo käytettäväksi hengitystietautien hoidossa | |
| TWI850283B (zh) | 用於治療糜爛性手部骨關節炎的孟魯司特 | |
| JP6454436B1 (ja) | ペマフィブラートを含有する医薬 | |
| JP2698865B2 (ja) | 筋緊張性ジストロフィー症治療剤 | |
| JP7621668B2 (ja) | 疾患の処置用の２－（ジエチルアミノ）エチル２－（４－イソブチルフェニル）プロピオネートの局所投与 | |
| JP2007008831A (ja) | 口内炎治療のための口腔用組成物 | |
| JP5303093B2 (ja) | テナトプラゾール及びヒスタミンｈ２受容体拮抗剤を組み合わせた医薬組成物 | |
| EP2809306A2 (en) | New pharmaceutical compositions of flurbiprofen and glucosamin | |
| JP6188784B2 (ja) | 炎症性および免疫性疾患の治療のための組成物 | |
| JP2019001830A (ja) | 医薬 | |
| JP2008143856A (ja) | 非ステロイド系抗炎症剤配合医薬 | |
| JPH0576925B2 (https=) | ||
| CA2202425A1 (en) | A novel anti-spasmodic and antiinflammatory composition and a process for the manufacture thereof | |
| JPS58164516A (ja) | 湿疹性皮膚疾患および薬疹治療剤 | |
| CN120093761A (zh) | 一种治疗冠心病的药物组合物 | |
| RU2024126016A (ru) | Лечение глиомы низкой степени злокачественности мирдаметинибом | |
| RU2025135054A (ru) | Ингибиторы ферропортина для лечения наследственного гемохроматоза (нг) |